Dr. Reddy's Delays Semaglutide Supply Due to API Quality Issue
On July 9, 2026, Dr. Reddy's Laboratories halted commercial supplies of its generic semaglutide injection after detecting an impurity during API production scale-up. The delay, expected until late October or early November, caused shares to drop nearly 6%. Torrent Pharmaceuticals voluntarily recalled select batches of Semalix pens as a precaution. No patient safety impact or recall risk was reported, and oral semaglutide tablets remain unaffected. The company now targets 6-7 million pens in Q3-Q4 FY27, down from 12 million.
Editorial summary awaiting refresh
Cross-source coverage
Wire timeline
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
Dr. Reddy's Laboratories (NYSE: RDY) announced a temporary delay in commercial supply of its semaglutide injection due to a scale-up issue with the active pharmaceutical ingredient (API). During validation testing of a scaled-up synthetic API manufacturing process, an impurity was found out of specification. CEO Erez Israeli emphasized that the issue only affects new validation batches, not previously shipped products, and there is no recall risk or patient safety concern. The company expects to complete validation work around September, with commercial API supply resuming in October and product supply potentially restarting in late October or early November. The delay will cause Dr. Reddy's to miss expected sales during July through October, but the company remains on track to supply 6-7 million semaglutide pens between Q3 and Q4 of fiscal 2027. The issue does not affect existing regulatory filings or oral semaglutide tablets.
Yahoo FinanceDr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
Dr. Reddy's Laboratories (NYSE:RDY) announced a temporary delay in commercial supply of its semaglutide injection due to a scale-up issue with the active pharmaceutical ingredient (API). An out-of-specification impurity was detected during validation testing of a scaled-up synthetic API manufacturing process. CEO Erez Israeli emphasized that the issue only affects new validation batches, not previously shipped products, and there is no recall or patient safety concern. The company expects validation work to complete around September, with commercial API supply potentially resuming in October and product supply to the market in late October or early November. Dr. Reddy's remains on track to supply 6-7 million semaglutide pens between Q3 and Q4 of fiscal 2027 (November through March), but acknowledges it will miss expected sales during July-October. The delay does not affect existing global regulatory filings or the company's oral semaglutide tablets.
Yahoo FinanceDr. Reddy's delays semaglutide supplies due to quality issue, shares fall
Dr. Reddy's Laboratories announced on July 9, 2026, that it has halted commercial supplies of its generic semaglutide after an issue with the active pharmaceutical ingredient (API). The impurity was discovered during a production scale-up, and commercial resupply is not expected until late October or early November. The company's shares dropped nearly 6% on the BSE. Torrent Pharmaceuticals issued a voluntary recall of select batches of Semalix injection pens manufactured by Dr. Reddy's. The company clarified there is no patient safety impact and that oral semaglutide tablets, which use a different API source, are unaffected. Dr. Reddy's now expects to sell 6-7 million pens in Q3-Q4 of FY27, down from its target of 12 million pens.
The Hindu: Latest News today from India and the World, Breaking news, Top Headlines and Trending News Videos.Dr. Reddy's Halts Semaglutide Supplies on Quality Concerns; Shares Plunge, Torrent Recalls Product
Dr. Reddy's Laboratories announced on July 9, 2026, that it has halted commercial supplies of its generic semaglutide due to an unknown impurity found in the active pharmaceutical ingredient (API) during a production scale-up. The company stated that the affected batches were not dispatched and there is no patient safety impact. The halt caused Dr. Reddy's shares to fall nearly 6% on the BSE. Torrent Pharmaceuticals voluntarily recalled select batches of its Semalix injection pens manufactured by Dr. Reddy's as a precaution. CEO Erez Israeli indicated that commercial supplies are unlikely to resume until late October or early November, significantly impacting the company's target of 12 million pens this year. The issue does not affect semaglutide oral tablets or existing regulatory filings.
The Hindu: Latest News today from India and the World, Breaking news, Top Headlines and Trending News Videos.Dr. Reddy's delays semaglutide supplies due to quality issue, shares hit
Dr. Reddy's Laboratories announced on July 9, 2026, that it will delay commercial supplies of semaglutide due to a quality issue with the active pharmaceutical ingredient (API). Certain batches were found out of specification, prompting an investigation. The company stated there is no impact on patient safety or existing regulatory filings. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Dr. Reddy's had launched its generic version in India after the patent expired in March 2026. The news caused the company's shares to drop 5.24% on the BSE. Dr. Reddy's scheduled a conference call to discuss the development.
The Hindu: Latest News today from India and the World, Breaking news, Top Headlines and Trending News Videos.